ZVRA: Strong U.S. growth, global expansion, and pipeline progress drive rare disease leadership
The organization is rapidly expanding its rare disease portfolio, achieving strong U.S. commercial traction in NPC, and is advancing global and pipeline initiatives. Financial strength and disciplined strategy support growth, with key milestones ahead in U.S. expansion, European approval, and vEDS…